Introduction {#s02}
============

Aging is characterized by a gradual functional decline. In mammals, aging occurs heterogeneously across multiple organ systems, causing a progressive deterioration that eventually results in tissue dysfunction. Consequently, age is a risk factor for many diseases ([@bib111]), such as cardiovascular disease ([@bib112]), dementia ([@bib119]), osteoporosis ([@bib121]), osteoarthritis ([@bib121]), cancer ([@bib31]), type 2 diabetes ([@bib54]), idiopathic pulmonary fibrosis (IPF; [@bib108]), and glaucoma ([@bib85]). Despite these links with human pathology, our understanding of the aging process remains limited. Although its biological causes remain largely unknown, studies in the past few decades have identified common cellular and molecular traits associated with aging ([@bib95]). The identification of so-called aging hallmarks has helped to conceptualize aging research and has hinted at the tantalizing prospect of delaying multiple age-related diseases by targeting the aging process.

Aging hallmarks can be divided into three categories: (1) primary, or the causes of age-associated damage; (2) antagonistic, or the responses to the damage; and (3) integrative, or the consequences of the responses and culprits of the aging phenotype. Senescence, a cellular response that limits the proliferation of aged or damaged cells ([@bib107]; [@bib106]), belongs to the antagonistic class ([Fig. 1](#fig1){ref-type="fig"}). Although senescence plays physiological roles during normal development and it is needed for tissue homeostasis, senescence constitutes a stress response triggered by insults associated with aging such as genomic instability and telomere attrition, which are primary aging hallmarks themselves. There is also an intimate link between senescence and the other antagonistic hallmarks of aging. For example, senescent cells display decreased mitophagy, resulting in an "old," defective mitochondrial network that may contribute to metabolic dysfunction in age ([@bib142]).

![**Senescence as a central hallmark of aging.** Telomere damage, epigenetic dysregulation, DNA damage, and mitochondrial dysfunction are primary drivers of damage in aging. Several of these drivers of damage can induce senescence. Senescence can in turn drive the consequential aging hallmarks in response to damage: stem cell exhaustion and chronic inflammation. Other responses to damage, such as proteostatic dysfunction and nutrient signaling disruption, are also integrally linked with the senescence response. Adapted from [@bib95].](JCB_201708092_Fig1){#fig1}

Senescence also influences the integrative aging hallmarks. Somatic multipotent stem cells facilitate tissue homeostasis; for example, hematopoietic stem cells (HSCs) renew the blood system. Stem cell exhaustion occurs with age, and the consequent decline in stem cell functionality and their capacity for renewal leads to tissue deterioration. For example, HSCs display a decreased success rate of transplantation when isolated from elderly patients ([@bib74]). This decline correlates with increased numbers of senescent HSCs ([@bib16]) and diminished immunity ([@bib49]), decreased numbers of naive B and T cells ([@bib102]), and reduced natural killer cell activity ([@bib104]). Somatic stem cell decline is not limited to high-turnover tissues. Neural stem cells (NSCs) experience reduced functionality, with limited neurogenesis capacity with age. This is marked by a twofold reduction in NSC numbers and a decreased proliferation, which correlates with increased expression of senescence markers in the regions where NSCs reside ([@bib105]). Mesenchymal stem cells ([@bib120]) and their descendants, satellite cells ([@bib135]; [@bib88]; [@bib138]), chondrocytes ([@bib93]), adipocytes ([@bib145]), and osteoclasts ([@bib21]), also display a reduced ability to self-renew with age that correlates with increased levels of senescence markers. This may have an impact in age-associated pathologies such as sarcopenia, cachexia, osteoporosis, and osteoarthritis ([@bib45]).

Altered intracellular communication is another of the integrative hallmarks of aging. In particular, chronic low-level inflammation is a serious complicating factor for many diseases in which risk increases with age ([@bib95]; [@bib43]). This detrimental role of inflammation is supported by inflammatory markers such as interleukin-1 (IL-1) and IL-6 acting as prognostic markers for diseases such as type 2 diabetes ([@bib30]), atherosclerosis ([@bib90]), and breakdown in stem cell function ([@bib38]; [@bib117]). Inflammatory responses are one of the major extrinsic effects of senescent cells ([@bib26]), which suggests that there is a link between senescence and altered intracellular communication. Aging influences a broad range of disease etiologies. Therefore, targeting the underlying aging machinery may provide broad-spectrum protection against many pathologies.

What is senescence? {#s03}
===================

Senescence is cellular program that induces a stable growth arrest accompanied by distinct phenotypic alterations, including chromatin remodeling, metabolic reprogramming, increased autophagy, and the implementation of a complex proinflammatory secretome ([@bib83]; [@bib128]). These complex changes to the cell largely serve to implement various aspects of senescence such as growth arrest and the senescence secretome. Despite the many facets of senescence, stable growth arrest is its defining characteristic. A permanent arrest is effective to ensure that damaged or transformed cells do not perpetuate their genomes. This growth arrest is implemented by the activation of p16^INK4a^/Rb and p53/p21^CIP1^ tumor suppressor networks ([Fig. 2](#fig2){ref-type="fig"}).

![**Pathways regulating senescence-mediated arrest.** The senescence growth arrest is regulated through two main pathways, p16^INK4a^/Rb and p53/p21^CIP1^, both which converge on repression of CDK4/6. The *INK4A/ARF* locus is normally silenced by Polycomb repressive complexes (PRCs) and becomes activated during senescence. The p53/p21^CIP1^ pathway is activated downstream of the DNA damage response (DDR) from repair-resistant DNA segments with chromatin alterations reinforcing senescence (DNA-SCARS).](JCB_201708092_Fig2){#fig2}

Historically, senescence was first identified by [@bib59] during serial passage of human fibroblasts. The limit to proliferation that senescence imposes was hypothesized as a barrier to cancer initiation. Senescence is indeed a powerful mechanism of tumor suppression ([@bib23]; [@bib55]). Senescence has also physiological roles during normal development ([@bib107]; [@bib140]), acting in concert with apoptosis to facilitate embryonic morphogenesis. In adult tissues, senescence is triggered primarily as a response to damage, allowing for suppression of potentially dysfunctional, transformed, or aged cells. The aberrant accumulation of senescent cells with age results in potential detrimental effects. In balance, although senescence is a biologically necessary process, it may come at a cost. The early research of [@bib59] hinted at a relationship between senescence and aging, but the consequent discovery that senescent cells accumulate in aged tissues has substantiated the hypothesis that senescence itself can drive aging.

Factors driving senescence {#s04}
==========================

Telomere damage driving senescence in aging {#s05}
-------------------------------------------

In adult tissues, senescence is engaged in response to different types of damage. One of the insults causing senescence is damage of the telomeres, highly repetitive DNA structures located at the end of chromosomes. Telomeres are protected by a multiprotein complex known as shelterin. By coating the telomere, shelterin prevents the activation of a DNA damage response, thereby preventing end-to-end chromosome fusions that would result in a telomere crisis ([@bib114]). Moreover, cells lacking shelterin components, such as POT1 or TRF2, suffer an aberrant DNA damage response and premature induction of senescence ([@bib35]). The end-replication problem is a consequence of the inability of DNA polymerases to synthesize DNA without a template, which occurs at telomeres. This results in telomeres that shorten progressively with each cell cycle division. Embryonic tissues circumvent this erosion by expressing telomerase, a ribonucleoprotein complex that serves to concatenate DNA to the ends of chromosomes, thus providing a template for DNA synthesis ([@bib109]). Repeated cell division in adult tissues that lack telomerase, however, results in progressive erosion of DNA, reduced shelterin binding, and senescence. As an organism ages, cells accumulate more divisions. This results in increased telomere erosion and senescence. But the extent to which telomere erosion drives senescence during aging and contributes to the aging process itself remains unknown.

Supporting the causative role of telomere erosion in aging, deletion of telomerase in mice eventually results in premature aging ([@bib89]). This phenotype can be rescued by transient activation of telomerase reverse transcription expression in mice using a telomerase reverse transcription estrogen receptor construct. Cells isolated from these mice proliferate normally in vitro, and deterioration in multiple tissues is reduced ([@bib67]). This evidence correlates with studies showing that fibroblasts or T cells derived from centenarians reset their telomeres, which results in rejuvenation and sustained proliferation ([@bib87]). Similarly, stimulation of T cells derived from serially transplanted HSCs results in telomerase expression and rejuvenation ([@bib4]). Shortened telomeres are associated with many pathologies such as liver cirrhosis ([@bib126]) and correlate with an increase in mortality in people older than 60 years ([@bib15]). Correlative evidence supports telomere erosion as a major driver of aging decline, yet this is challenged by mammals such as laboratory mice (*Mus musculus*), whose telomeres do not reach a critical limit during normal aging. Telomere length is also not predictive of aging deterioration in mice ([@bib127]), highlighting that alternative factors could also drive aging.

Metabolic dysfunction as a driver of senescence {#s06}
-----------------------------------------------

Several lines of evidence suggest that aging is the result of a complex amalgam of damages such as metabolic and proteostatic dysfunction ([@bib95]). Metabolic dysfunction relates to aging at the organismal and molecular level. Multiple studies have demonstrated that caloric restriction can retard the aging decline ([@bib103]). Molecularly, pathways fine-tuning metabolic regulation, such as the mTOR or insulin pathway, have also been linked to increased health span and life span ([@bib131]; [@bib58]). mTORC1 integrates inputs from nutrient and growth signals to regulate general cellular processes such as protein and lipid synthesis, autophagy, and metabolism ([@bib129]). In this regard, mTOR is able to regulate the senescence-associated secretory phenotype (SASP), autophagy, and senescent growth arrest ([@bib61]; [@bib86]). The connection between autophagy and senescence is complex; although there is an increase in autophagy during senescence that serves to regulate SASP production ([@bib110]), inhibition of autophagy can induce senescence through metabolic and proteostatic dysfunction ([@bib48]), further emphasizing the intricate connection between metabolic stress and senescence in aging.

Sirtuins constitute another molecular link between metabolism and senescence. Sirtuins are ribosyltransferases with a wide array of functions, such as metabolism regulation and DNA repair ([@bib63]). Their role in senescence is antagonistic; SIRT1 deacetylates p53, promotes its degradation ([@bib136]), and facilitates senescence bypass, whereas SIRT6 deacetylates H3K18 to prevent mitotic errors and suppress senescence ([@bib144]).

In addition to these forms of damage, general stress is sensed by other mechanisms such as activation of MAPK p38 or induction of p16^INK4a^. These pathways are up-regulated in response to oxidative stress, DNA damage, telomere attrition, or oncogene activation. Substantiating their role in aging, activation of MAPK p38 or induction of p16^INK4a^ limits the proliferative potential of HSCs and yields proaging phenotypes ([@bib64]; [@bib7]). Overall, it is likely that the accumulation of senescent cells during aging reflects a gradual increase of different types of damage in different tissues.

Pathways regulating the senescence growth arrest {#s07}
================================================

Despite the multifaceted nature of senescence, the induction of stable growth arrest is the defining characteristic of senescence. Moreover, stable arrest is paramount to halt the propagation of dysfunctional cells. Two tumor suppressor pathways, p53 and the p16/Rb, are responsible for the implementation of this growth arrest.

p53 and senescence {#s08}
------------------

Senescence inducers such as telomeric attrition and oncogenic or oxidative stress cause DNA damage. DNA damage results in increased deposition of γH2Ax and 53BP1 in chromatin that in turn activates a kinase cascade involving first ATM and ATR and then CHK1 and CHK2, eventually resulting in p53 activation ([@bib29]; [@bib46]). p53 induces transcription of the cyclin-dependent kinase inhibitor p21^CIP1^. In turn, p21^CIP1^ blocks CDK4/6 activity, resulting in hypophosphorylated Rb and cell cycle exit ([@bib29]). Although transient increases in p53 levels can enact a quiescent state and activate DNA repair processes, during senescence, there is a sustained induction of p53 ([@bib128]; [@bib80]). This is a result of damage occurring in repair-resistant regions of the genome known as DNA segments with chromatin alterations reinforcing senescence, such as telomeres ([@bib124]; [@bib46]), that allow for a permanent arrest of the cell cycle by persistent induction of p21^cip1^. Given the key roles of p53, additional regulatory layers exist. For example, the induction of ARF, a product of the *INK4/ARF* locus, sequesters the ubiquitin ligase MDM2, contributing to increased levels of p53. Recently, the interaction between Forkhead box protein O4 (FOXO4) and p53 has been shown to play an important role in modulating p53 localization and transcriptional activity during senescence ([@bib5]). Interestingly FOXO transcription factors regulate aging, with FOXO activity in *Drosophila melanogaster* leading to delayed aging in response to disrupted protein homeostasis and oxidative stress ([@bib34]).

The INK4/ARF locus in senescence {#s09}
--------------------------------

Three tumor suppressors reside in the *INK4/ARF* locus: p16^INK4a^ and ARF, which are both encoded by the *CDKN2A* gene, and p15^INK4b^, which is encoded by *CDKN2B*. Two of these, p15^INK4b^ and p16^INK4a^, are CDKIs, like p21^CIP1^, that affect the cell cycle by binding and inhibiting CDK4 and CDK6. In contrast, ARF inhibits MDM2, thereby allowing cross talk with the p53/p21^CIP1^ pathways. Conversely, p53 can regulate expression of ARF through a negative feedback loop, as demonstrated by elevated ARF expression in p53^−/−^ mouse embryonic fibroblasts ([@bib57]).

Given this unusual concentration of three tumor suppressors in barely 35 kb, this locus plays a key regulatory role and is frequently mutated in cancer ([@bib50]; [@bib72]). Genome-wide association studies have also identified various genomic variants occurring at the *INK4/ARF* locus as major risk factors for atherosclerosis, stroke, and diabetes, among other pathologies ([@bib68]). However, most of these are found in noncoding regions, and the precise mechanism of action is unclear. The *INK4/ARF* locus behaves as a senescence sensor. In young, normal cells, the *INK4/ARF* locus is epigenetically silenced through deposition of repressive H3K27me3 marks ([@bib11]). H3K27 methylation is controlled by Polycomb repressive complexes (PRC2 and PRC1). Disrupting PRC1 or PRC2 activity by depleting the expression of some of their components, such as BMI1, CBX7, or EZH2, derepresses p16^INK4a^ and induces senescence ([@bib65]; [@bib51]; [@bib11]). There is still debate over how Polycomb is recruited to the *INK4/ARF* locus. It has been proposed that a long noncoding RNA, ANRIL, divergently transcribed from the *INK4/ARF* locus ([@bib155]; [@bib75]), and transcription factors such as those of the homeobox family can contribute to recruiting PRCs ([@bib96]).

Conversely, during senescence, the H3K27 histone demethylase JMJD3 plays a role in removing the repressive marks around the *INK4/ARF* locus, facilitating its induction ([@bib3]; [@bib9]). *INK4/ARF* induction can be observed in tissues during natural aging ([@bib76]; [@bib13]). In particular, p16^INK4a^ is considered an aging biomarker. With exceptions (such as during senescence-induced during development), p16^INK4a^ is also one of the best markers of senescence. An analysis of the pathways regulating p16^INK4a^ shows coincidences with those controlling development. This has been argued to formulate the theory that aging might be driven by gradual functional decay of developmental pathways ([@bib97]).

The SASP {#s10}
========

Besides growth arrest, the production of a complex mixture of secreted factors, termed the SASP or senescence-messaging secretome, is the most relevant phenotypic program implemented in senescent cells. Senescent cells secrete hundreds of factors that include proinflammatory cytokines, chemokines, growth factors, and proteases ([@bib81]; [@bib26]).

Regulation of the SASP {#s11}
----------------------

The specific combination of secreted factors is thought to depend on the cell type and the senescent inducer. However, many of the key effectors of the SASP and its regulatory mechanism seemed to be shared. Nuclear factor κB (NF-κB) and CCAAT/enhancer--binding protein beta are the key transcriptional SASP regulators ([@bib1]; [@bib82]). DNA damage ([@bib123]), p38α MAPK ([@bib44]), mTOR ([@bib61]; [@bib86]), mixed lineage leukemia 1 ([@bib14]), and GATA4 ([@bib70]) are also able to regulate the SASP. Recently, sensing of cytoplasmic chromatin by the cGAS/STING pathway has been suggested as a trigger for SASP induction ([@bib39]; [@bib52]). There are additional layers of SASP regulation. For example, mTOR controls IL-1α translation to regulate the SASP ([@bib86]). In addition, mTOR indirectly regulates the activity of ZFP36L1, an RNA-binding protein that binds to AU-rich elements in the 5′-end of inflammatory transcripts, targeting them for degradation ([@bib61]). There is also a global remodeling of enhancers in senescent cells, and the recruitment of BRD4 to superenhancers adjacent to SASP genes is needed for their induction ([@bib143]).

The complex composition of the SASP means that different subsets of the SASP, such as the proinflammatory and TGF-β secretomes, can be regulated independently. The proinflammatory arm of the SASP is regulated by IL-1 signaling ([@bib2]). IL-1α partially recapitulates the inflammatory SASP in vitro, and inhibiting the NLRP3 inflammasome, which processes IL-1β, can blunt the SASP ([@bib2]). Conversely, the juxtacrine Notch signaling pathway promotes the secretion of a TGF-β--enriched secretome ([@bib62]).

Functions of the SASP {#s12}
---------------------

The SASP is responsible for many of the positive and negative functions attributed to senescent cells ([Fig. 3](#fig3){ref-type="fig"}) ([@bib81]). One of the major functions of the SASP is to recruit the immune system to eliminate senescent cells. The SASP mediates the activation and recruitment of both adaptive and innate immune cells ([@bib152]; [@bib71]). In general terms, the effects are positive. During tumor initiation, SASP-mediated immune recruitment acts as an extrinsic tumor suppressor mechanism ([@bib152]; [@bib71]), and the recruitment of macrophages is a key step in fibrosis resolution ([@bib78]). In contrast, SASP-mediated recruitment of immature myeloid cells has immune suppressive effects on prostate and liver cancer ([@bib36]; [@bib40]). In addition, the SASP can stimulate tumorigenesis by promoting angiogenesis (e.g., via VEGF and CCL5; [@bib24]; [@bib42]) or tumor growth (e.g., via GROα and Osteopontin; [@bib79]; [@bib115]), among other mechanisms. Specific components of the SASP have other physiological functions, such as contributing to fibrotic tissue remodeling, whereby matrix metalloproteinases (MMPs) contribute to degrade fibrotic plaques in the ECM that may be beneficial in the context of liver fibrosis and wound healing ([@bib78]; [@bib32]).

![**Functions of the SASP.** The SASP mediates many of the cell-extrinsic functions of senescent cells. Among those it reinforces several aspects of senescence including growth arrest and the SASP itself via an autocrine loop. The SASP also recruits immune cells, such as macrophages, neutrophils, and natural killer (NK) cells to phagocytose and eliminate the senescent cell. Secretion of MMPs and factors such as VEGF can remodel the surrounding tissue, inducing angiogenesis and reducing fibrosis. Finally, secretion of molecules such as TGF-β can spread the senescence phenotype in a paracrine manner to surrounding cells.](JCB_201708092_Fig3){#fig3}

Recently, it has been postulated that senescent cells accumulating in response to tissue damage can also promote stemness and reprogramming ([@bib122]). However, how this fits with the increased number of senescent cells but decreased stemness potential observed during aging is unclear. On the other hand, factors secreted by senescent cells can reinforce the senescent phenotype, potentially exacerbating senescence during aging. IL-8, GROα, IL-6, and IGBP-7 are among the specific SASP components reinforcing senescence ([@bib1]; [@bib82]; [@bib149]). Moreover, senescent cells can also induce a so-called paracrine senescence response ([@bib2]). This autocrine reinforcement or paracrine transmission of senescence could potentially explain some of the detrimental effects of aberrant accumulation of senescent cells during aging. During aging, the SASP is thought to be partially responsible for persistent chronic inflammation, also known as inflammaging, that contributes to multiple age-related phenotypes. This contribution of SASP in inflammaging is beginning to be investigated using senolytic models. The direct elimination of senescent cells in aged kidney ([@bib7]; [@bib5]), heart, spleen, lung, liver ([@bib7]), and osteoarthritic knee ([@bib69]) reduced levels of IL-6 and IL-1β (both markers of chronic inflammation). It would be pertinent in future aging therapies to understand how specific aspects of the SASP contribute to the deterioration or protection of tissues.

Senescence: Bystander or participant in age-related pathologies? {#s13}
================================================================

Although the contribution of senescence to aging has been long suspected, only recently has the connection been confirmed. This has been made possible by the use of molecular biomarkers of senescence and the establishment of novel genetic models to study the role of senescent cells in vivo.

Senescence regulatory networks and aging in vivo {#s14}
------------------------------------------------

Expression of the components of the *INK4/ARF* locus correlates with aging, and p16^INK4a^ can be used as a prognostic marker for some age-related diseases, such as IPF and glomerulosclerosis ([@bib101]; [@bib94]). Furthermore, p16^INK4a^ accumulates during aging. For example, p16^INK4a^ expression increases with age in the islet of Langerhans ([@bib60]), renal cortex ([@bib101]), and fat tissue ([@bib151]; [@bib7]), among other areas ([@bib76]). Its knockout also mitigates functional decline and proliferative exhaustion upon HSC transplantation ([@bib66]). Although these studies suggest that p16^INK4a^ accumulation is detrimental during aging, increased gene dosage of *INK4/ARF* in super-p16 mice does not result in reduced life span. The possible detrimental effects cause by p16^INK4a^ overexpression may be outweighed by their clear tumor suppressive benefits, with a threefold reduction in tumor incidence ([@bib99]). Similarly, p53^−/−^ can ameliorate some of the effects of severe progeria mutants such as Ku80^−/−^, mTR^−/−^, and Zmpste24^−/−^ ([@bib20]; [@bib91]; [@bib148]), but the resulting increase in tumorigenesis obscures potential increases in life span. Mice with extra copies of p53 or p19^ARF^ are more resistant to tumors and display delayed aging ([@bib47]; [@bib98]).

Visualizing senescence in vivo {#s15}
------------------------------

One of the biggest hindrances to investigating senescence in vivo has been the lack of robust, consistent markers. Most studies of senescence in aged tissues have relied on usage of senescence-associated β-galactosidase (SA-β-Gal) staining or the lack of proliferative markers such as Ki67. However, these may yield mixed results. For example, macrophages display elevated levels of SA-β-Gal activity. The use of additional senescence markers, such as lipofuscin, which accumulates in the cytoplasm of senescent cells, could be applied to bridge this gap ([@bib132]).

Another useful tool that has emerged is the use of bioluminescent senescence reporters. With the advent of p16^INK4a^-LUC mice expressing a luciferase reporter under the control of a p16^INK4a^ promoter, there is now confirmation that multiple tissues show an exponential age-related increase in p16^INK4a^ expression that correlates with higher levels of proinflammatory factors or SASP components ([@bib153]; [@bib13]).

Evaluating the consequences of targeting senescence during aging {#s16}
----------------------------------------------------------------

Establishing causality of a gene in diseases such as cancer is usually a matter of generating appropriate knockout or overexpression mouse models. To evaluate the role of senescence in aging that approach gets complicated by the tumor suppressive roles of the *INK4/ARF* locus and p53 (see Pathways regulating the senescence growth arrest section). Seminal studies by Baker et al., first in progeroid BubR1 mice ([@bib6]) and later in naturally aged mice ([@bib7]), demonstrated that by expressing an inducible suicide gene under the control of the p16^INK4a^ promoter it is possible to ablate senescent cells and improve health span. The elimination of senescent cells improved several age-associated conditions, delayed tumor formation, and ameliorated the side effects of chemotherapy ([@bib7]; [@bib33]; [@bib5]). The role of p16^INK4a^-positive senescent cells in age-related pathologies has been further confirmed by additional studies using other p16^INK4a^-based senescence ablation systems such as p16-3MR and INK-NTR mice ([@bib32]; [@bib19]). These studies have finally confirmed that senescence causes, or at least contributes to, aging.

Senescence, the SASP, and age-related inflammation {#s17}
--------------------------------------------------

There is clear evidence suggesting how the SASP participates in the clearance of premalignant cells or contributes to tumor progression ([@bib71]; [@bib40]). Although it has been hypothesized that the SASP is responsible for tissue dysfunction during aging, we still lack direct evidence for the roles that the SASP may play in aging ([@bib106]).

IL-1α, IL-6, TNF, and NF-κB activity and other inflammatory factors have been found to increase in tissues with age and inhibition of NF-κB confers resistance to progeroid conditions ([@bib146]). The detrimental role for chronic inflammation during aging is further supported by clinical data ([@bib90]; [@bib12]; [@bib37]; [@bib8]). Aging phenotypes such as frailty ([@bib139]) correlate with increased levels of proinflammatory factors. The increased levels of chronic inflammation in these instances are collectively termed inflammaging ([@bib43]). The reason for such increases in levels of proinflammatory molecules remains unknown. Although accumulated damage and lifelong antigenic load may undoubtedly contribute to this increase in inflammation, senescence may also help mediate inflammaging.

This contribution of senescence to inflammaging may be via several coalescing effects, the first being through the SASP. As damage accumulates in tissues, the number of senescent cells and their SASP also increases. This process is usually resolved by clearance of the senescent cells by the immune system ([@bib71]). In aged individuals, however, senescence also contributes to a decline in immune function termed immunosenescence, thereby compromising the clearance of senescent cells and exacerbating inflammation. Emerging studies using genetic systems or drugs ablating senescent cells suggest that the elimination of senescent cells reduces inflammation across tissues ([@bib7]; [@bib69]). Future studies will need to establish the causal link between the SASP, chronic inflammation, and tissue dysfunction. These might require the generation of novel mouse models that take advantage of our knowledge on SASP regulation.

Contribution of senescence to age-related diseases {#s18}
==================================================

Now that a general causative role for senescence during aging has been established, the next step is to identify how senescence contributes to different age-related pathologies such as glaucoma ([@bib92]) or osteoarthitis ([@bib69]; [Fig. 4](#fig4){ref-type="fig"}). Thanks to the use of senolytic drugs and genetic models for senescence ablation, we are progressing quickly in that task.

![**Involvement of senescence in disease.** Establishment of robust biomarkers of senescence, usage of genetic knockout models and senolytic models are expanding our knowledge on the age-related diseases in which senescence plays a role.](JCB_201708092_Fig4){#fig4}

Opposing roles for senescence in cancer {#s19}
---------------------------------------

Age is a strong prognostic marker of reduced survival across many cancers ([@bib31]). Senescence is a strong tumor suppressor mechanism that limits cancer initiation through both cell-intrinsic ([@bib22]) and cell-extrinsic mechanisms ([@bib71]). However, there is strong evidence suggesting that through the SASP, aged tissues provide a supportive niche for cancer ([@bib26]). Senescent cells can contribute to tumor progression by enhancing the proliferative potential of cancer cells ([@bib79]) or contributing to epithelial to mesenchymal transition ([@bib25]). Therefore, the increased numbers of senescent cells present in aged tissues could contribute to the increased incidence of cancer with age. Supporting this, a delayed onset in tumor formation is observed when senescent cells are eliminated ([@bib7]). Senolytic therapy also reduces the incidence of metastasis, the leading cause of cancer-related deaths ([@bib33]).

Renal dysfunction {#s20}
-----------------

Aged individuals often display a reduced glomerular filtration rate and cortical volume that can result in glomerulosclerosis and nephron atrophy, both of which are associated with increased expression of p16^INK4a^ and p53 ([@bib100], [@bib101]). Senescence has detrimental effects in most renal diseases analyzed ([@bib141]). Ablation of senescent cells protects against glomerulosclerosis and improves kidney function in aged mice ([@bib7]).

Type 2 diabetes {#s21}
---------------

One of the largest risk factors for the development of type 2 diabetes is age. Several genome-wide association studies of type 2 diabetes have highlighted variants at the *INK4/ARF* locus, suggesting a possible link between senescence and diabetes ([@bib157]; [@bib68]). In addition, senescence markers and IL-1β are elevated in β cells from diabetic mice ([@bib137]; [@bib37]). Surprisingly, although p16^INK4a^ expression drove a decline in β cell regenerative capacity and predisposed mice to mild diabetes ([@bib77]; [@bib17]), senescent β islets increased insulin secretion, making it unclear how senescence contributes to maintain glucose homeostasis ([@bib60]).

IPF {#s22}
---

Fibrosis is a pathological condition whereby tissue accumulates ECM proteins such as collagen, resulting in tissue scarification, usually in response to damage. Senescence appears to have both beneficial and detrimental roles during fibrosis and wound healing. Secretion of MMPs, which occurs as part of the SASP, could help in the resolution of fibrotic plaques ([@bib28]). Conversely, fibroblasts and tissues isolated from IPF patients display increased levels of SA-β-Gal staining and p21^CIP1^, suggesting a link with senescence ([@bib154]; [@bib130]). The detrimental nature of senescence in IPF was recently demonstrated using senolytics. Elimination of senescent fibroblasts in a mouse model of lung fibrosis reduced expression of profibrotic SASP components and improved pulmonary function ([@bib130]).

Nonalcoholic fatty liver disease {#s23}
--------------------------------

Cirrhosis is the pathological outcome from liver fibrosis and nonalcoholic fatty liver disease, which in turn is a result of hepatic steatosis, the abnormal accumulation of lipids in hepatocytes ([@bib116]; [@bib56]). Senescence is associated with liver fibrosis ([@bib73]) and cirrhosis ([@bib150]). The risk of developing nonalcoholic fatty liver disease increases with age ([@bib56]) and is predicted by the presence of senescent hepatocytes ([@bib116]). The elimination of senescent cells using INK-ATTC mice reduces liver fat accumulation ([@bib113]). The role of senescence in the liver is complex, however, because knocking out p53 or p16^INK4a^ increases liver fibrosis ([@bib78]). Moreover, senescent hepatic stellate cells down-regulate collagen and up-regulate MMPs and cytokines that could remodel fibrotic plaques and recruit macrophages ([@bib78]).

Cardiovascular disease {#s24}
----------------------

The risk of developing atherosclerosis and cardiomyopathy and their respective conditions, coronary heart disease and heart failure, increases with age. In the case of atherosclerosis, the role of senescence has been confirmed using senolytic models ([@bib19]). Ablation of senescent cells improved the stability of plaques and reduced both the incidence and progression of plaque formation. Senescent cells were initially identified in atherosclerosis in vascular smooth muscle cells at the site of the plaque ([@bib147]). Subsequent studies showed that macrophages were the primary senescent cell present with higher levels of SA-β-Gal staining and SASP production, suggesting their key contribution to coronary heart disease ([@bib19]). Cardiomyocyte atrophy is one of the underlying causes of myocardial infarction in the elderly ([@bib111]). It is unclear how ablation of senescent cells protects against cardiomyocyte hypertrophy in aged mice and provides resistance to cardiac stress ([@bib7]).

Osteoarthritis {#s25}
--------------

Lifelong wear and tear on ligaments is a significant risk factor for the development of arthritis. Failure of chondrocytes to produce cartilage results in degradation of joints and immobilization. Expression of p16^INK4a^ in these cells correlates with severity and progression of the disease ([@bib118]). Moreover, when mice were subjected to an acute trauma to model osteoarthritis, senescent cells accumulated in the site of the injury ([@bib84]). Clearance of these senescent cells using senolytics resulted in the increased functionality of the remaining chondrocytes with rejuvenation of cartilage soon after ([@bib69]).

Decline in immune function with age {#s26}
-----------------------------------

One of the primary risk factors for complications in end-of life care is infection. The inability of the body to raise a response to immune offenses is caused by a functional decline in HSCs. The accumulation of senescent HSCs with age contributes to immune decline and senescence bypass allows for stem cell rejuvenation. Interestingly, the removal of these cells restored the functionality of HSCs and increased myeloid, B, and T cell numbers in transplant experiments ([@bib16]).

Sarcopenia {#s27}
----------

Muscle stem cells (MuSCs) undergo a decline in their ability to differentiate and facilitate repair of muscle tissue, which is hypothesized to be the underlying cause of age-dependent muscle wasting or sarcopenia. MuSCs are quiescent unless stimulated to repair muscle ([@bib53]). However, with age, they become senescent, up-regulating p16^INK4a^ ([@bib138]). The elimination of senescent MuSCs increases the ability of the remaining MuSCs to form muscle cell colonies ([@bib16]). Additionally, inhibition of p38 or p16^INK4a^ bypasses MuSC senescence and strengthens muscle in geriatric mice ([@bib27]; [@bib138]).

Age-related cachexia {#s28}
--------------------

Loss of adiposity and loss of muscle mass in aged individuals are primary contributors to age-dependent wastage or cachexia. White adipose tissue isolated from aged mice display SA-β-Gal activity ([@bib7]). Removal of senescent cells from mice leads to increased adiposity and prevents mass loss in aged mice ([@bib7]). Recently it has been shown that bypass of senescence or senolysis restores adipose beiging and adipogenesis and improves metabolic function in aged mice ([@bib151]; [@bib10]). This suggests that senescent cells prevent adipocyte differentiation and contribute to an age-dependent loss of adaptive thermogenic capacity and metabolic dysfunction.

Targeting senescence during aging {#s29}
=================================

Because of the detrimental nature of senescence in the etiology of numerous diseases, disrupting or preventing senescence can delay health decline during aging. Inhibition of p38, disruption of p53 and p16, or lengthening of telomeres have all been shown to benefit aging phenotypes but carry a major caveat, as they can increase the incidence of cancer ([@bib133]; [@bib64]; [@bib66]; [@bib134]). The selective elimination of senescent cells has revealed to be a safer route to target senescence during aging.

ABT-263, otherwise known as navitoclax, is a BH3 mimetic that blocks the interaction between antiapoptotic BCL-2 proteins and their targets, thereby releasing the brakes on the cell death machinery, and has been used to treat various cancers ([@bib125]; [@bib16]). Its senolytic activity is explained by an overreliance of senescent cells on BCL-xL and BCL-w, both of which are up-regulated during senescence ([@bib156]). However, usage of navitoclax as a prophylactic senolytic drug is unlikely because of its severe thrombocytopenic and neutropenic effects ([@bib125]). Recently, it has been shown that localization of p53 to the nucleus by FOXO4 protects against p53 engaging the p53-mitochondrial signaling axis and apoptosis therein ([@bib5]). Treatment of mice with a FOXO4 inhibitor peptide, FOXO4 D-retro inverso isoform, can delay different aging phenotypes. As with navitoclax, however, special attention must be paid to unintended effects of FOXO4 D-retro inverso isoform. For example, p21^CIP1^ expression fell markedly in senescent cells treated with the peptide.

Initial studies regarding senolytics are promising, but there are still lingering unknowns with regards to their effectivity as therapies. Senescent cells were observed to reappear after cessation of senolytic treatment in a model of osteoarthritis ([@bib69]). This could reflect unresolved damage from the anterior cruciate ligament injury surgery used in this study, although there is also the possibility that removal of senescent cells without targeting the causes that induce their accumulation could limit the benefits of senolytics. Another potential problem of using senolytics is an acceleration of stem cell exhaustion.

The clinical population in which senolytics could be used includes already-infirmed patients whose immune systems might be compromised. If senescent cells are eliminated and account for ∼1--5% of cells in aged tissues ([@bib132]), where do they go? Apoptotic cells mark themselves for phagocytosis by the immune system with special "find me" and "eat me" signals. Can we expect an immune system that was unable to clear aberrantly accumulated senescent cells to infiltrate and clear apoptotic bodies? Without clearance of apoptotic bodies, secondary necrosis could result in the release of proinflammatory, danger-associated molecular patterns, further exacerbating systemic chronic inflammation. This could limit the effective therapeutic window for senolytic drugs. Although these are potential caveats for senolytic therapies, they may be significantly outweighed by their benefits. In addition, the senescence program varies across tissues, raising the possibility of identifying "tissue-specific" senolytics, which could minimize side effects. With these unknowns, it will be critical to validate the kinetics of senescent cells clearance using robust markers of senescence and improved methods for identifying senescent cells ([@bib41]).

Exploring alternative approaches to target the detrimental effects of senescence without resorting to senolytics may also be worthwhile. One such approach would be targeting the SASP. Candidates to suppress or modulate the SASP include rapamycin, BRD4, NF-κB, or p38 inhibitors ([@bib18]; [@bib44]; [@bib61]; [@bib86]; [@bib143]). Possible side effects of this strategy could include blunting the senescent response, exacerbation of the accumulation of senescent cells, or immunosuppression. However, there are many potential routes for the development of new SASP modulators, which can be helped in no small part by improvements our understanding of how the SASP is regulated.

In summary, the past few years have unveiled a key role for senescence in aging. The advent of powerful genetic and pharmacological tools to dissect this relation should improve our understanding of the mechanisms through which the accumulation of senescence cells leads to age-related physiological decline. It should also inform in the development of new therapeutic approaches. Moreover, if targeting senescence using senolytics or by other strategies such as SASP-modulating drugs succeeds, it could not only contribute to the treatment of specific diseases but also improve the general health span of aged individuals.
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